0001213900-24-011800.txt : 20240313 0001213900-24-011800.hdr.sgml : 20240313 20240209070002 ACCESSION NUMBER: 0001213900-24-011800 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 CORRESP 1 filename1.htm

 

Scinai Immunotherapeutics Ltd.

Jerusalem BioPark, 2nd Floor

Hadassah Ein Kerem Campus

Jerusalem, Israel

 

February 9, 2024

 

Via EDGAR Transmission

 

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

  Re: Scinai Immunotherapeutics Ltd.
    Registration Statement on Form F-3
    Filed January 30, 2024
    Registration No. 333-276767

 

Ladies and Gentlemen:

 

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on February 13, 2024 at 9:15 a.m. Eastern Time or as soon thereafter as practicable, or at such later time as Scinai Immunotherapeutics Ltd. (the “Company”) or its counsel may request via telephone call to the staff.

 

Please contact Steven A. Lipstein of Lucosky Brookman LLP, counsel to the Company, at (732) 395-4416, or in his absence, Perry Wildes of Goldfarb Gross Seligman & Co., counsel to the Company, at + 972-3-607-4444, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

 

  Sincerely yours,
     
  Scinai Immunotherapeutics Ltd.
     
  By: /s/ Amir Reichman
    Amir Reichman
    Chief Executive Officer

 

cc: Steven A. Lipstein, Lucosky Brookman LLP
  Perry Wildes, Goldfarb Gross Seligman & Co.